{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:06:42Z","timestamp":1789009602762,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cjcopen.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CJC Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cjco.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:02:00Z","timestamp":1779346920000},"page":"1249-1258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["PaO2\/FiO2 Ratio As an Exploratory Indicator of Oxygenation Changes in Acute Decompensated Heart Failure Treated with Intravenous Tolvaptan"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0092-3224","authenticated-orcid":false,"given":"Hiroki","family":"Hoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yodo","family":"Gatate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiru","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahide","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjco.2026.05.007_bib1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjco.2026.05.007_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC)","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2026.05.007_bib3","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1253\/circj.CJ-25-0002","article-title":"JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure","volume":"89","author":"Kitai","year":"2025","journal-title":"Circ J"},{"key":"10.1016\/j.cjco.2026.05.007_bib4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/eurjhf\/hfq045","article-title":"Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine","volume":"12","author":"Gheorghiade","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjco.2026.05.007_bib5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.05.007_bib6","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMoa1210357","article-title":"Ultrafiltration in decompensated heart failure with cardiorenal syndrome","volume":"367","author":"Bart","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.05.007_bib7","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1253\/circj.CJ-17-1386","article-title":"Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan: observations from the prospective, multicenter Kyoto Congestive Heart Failure (KCHF) Registry","volume":"82","author":"Yaku","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.cjco.2026.05.007_bib8","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/CCM.0000000000002017","article-title":"Evaluating pulmonary function: an assessment of PaO2\/FiO2","volume":"45","author":"Feiner","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cjco.2026.05.007_bib9","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41569-020-0379-7","article-title":"Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment","volume":"17","author":"Boorsma","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjco.2026.05.007_bib10","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1253\/circj.CJ-19-0158","article-title":"Real-world effectiveness and tolerability of tolvaptan in patients with heart failure: final results of the Samsca post-marketing surveillance in heart failure (SMILE) study","volume":"83","author":"Kinugawa","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.cjco.2026.05.007_bib11","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jchf.2024.05.020","article-title":"We must change our approach to decongestion in acute heart failure","volume":"12","author":"Howlett","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjco.2026.05.007_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/jcm13030720","article-title":"Preliminary report of intravenous tolvaptan sodium phosphate (Samtas) treatment in decompensated heart failure","volume":"13","author":"Nakamura","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.cjco.2026.05.007_bib13","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1183\/20734735.0204-2019","article-title":"Oxygen devices and delivery systems","volume":"15","author":"Hardavella","year":"2019","journal-title":"Breathe (Sheff)"},{"key":"10.1016\/j.cjco.2026.05.007_bib14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejim.2021.11.010","article-title":"Phenotyping congestion in patients with acutely decompensated heart failure with preserved and reduced ejection fraction: the DRY-OFF study","volume":"97","author":"Cogliati","year":"2022","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.cjco.2026.05.007_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jjcc.2019.03.003","article-title":"Systolic blood pressure on admission as a marker of fluid re-distribution in acute heart failure","volume":"74","author":"Uehara","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.cjco.2026.05.007_bib16","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1161\/CIRCRESAHA.121.318186","article-title":"Pathophysiology and therapeutic approaches to acute decompensated heart failure","volume":"128","author":"Njoroge","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.cjco.2026.05.007_bib17","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.jacc.2017.04.042","article-title":"Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure","volume":"69","author":"Matsue","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.05.007_bib18","first-page":"2526","article-title":"Acute respiratory distress syndrome: the Berlin definition","volume":"307","author":"Ranieri","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.05.007_bib19","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jchf.2019.07.008","article-title":"Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes","volume":"7","author":"Platz","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjco.2026.05.007_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/srep39426","article-title":"Prognostic value of pulmonary congestion assessed by lung ultrasound imaging during heart failure hospitalisation: a two-centre cohort study","volume":"6","author":"Coiro","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjco.2026.05.007_bib21","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/ehf2.14494","article-title":"The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry","volume":"10","author":"Nishikawa","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cjco.2026.05.007_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1253\/circj.CJ-21-0430","article-title":"Pharmacokinetics, pharmacodynamics, efficacy, and safety of OPC-61815, a prodrug of tolvaptan for intravenous administration, in patients with congestive heart failure: a phase II, multicenter, double-blind, randomized, active-controlled trial","volume":"86","author":"Sato","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.cjco.2026.05.007_bib23","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cjco.2026.05.007_bib24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2024.01.029","article-title":"Enhanced decongestive therapy in patients with acute heart failure: JACC review topic of the week","volume":"83","author":"Cotter","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjco.2026.05.007_bib25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed with the special contribution of the Heart Failure Association of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2026.05.007_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132456","article-title":"Diuretic resistance in acute heart failure: proposal for a new urinary sodium-based definition","volume":"415","author":"Pellegrino","year":"2024","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjco.2026.05.007_bib27","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","article-title":"Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial","volume":"44","author":"Trull\u00e0s","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjco.2026.05.007_bib28","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa0912613","article-title":"Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure","volume":"363","author":"Massie","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjco.2026.05.007_bib29","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["CJC Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X2600212X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589790X2600212X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:21:07Z","timestamp":1789006867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589790X2600212X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2589790X2600212X"],"URL":"https:\/\/doi.org\/10.1016\/j.cjco.2026.05.007","relation":{},"ISSN":["2589-790X"],"issn-type":[{"value":"2589-790X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PaO2\/FiO2 Ratio As an Exploratory Indicator of Oxygenation Changes in Acute Decompensated Heart Failure Treated with Intravenous Tolvaptan","name":"articletitle","label":"Article Title"},{"value":"CJC Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjco.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}